Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: SIGIRR

Gene summary for SIGIRR

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

SIGIRR

Gene ID

59307

Gene namesingle Ig and TIR domain containing
Gene AliasIL-1R8
Cytomap11p15.5
Gene Typeprotein-coding
GO ID

GO:0001816

UniProtAcc

Q6IA17


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
59307SIGIRRLZE4THumanEsophagusESCC1.35e-052.05e-010.0811
59307SIGIRRLZE7THumanEsophagusESCC1.27e-062.71e-010.0667
59307SIGIRRLZE8THumanEsophagusESCC1.04e-032.40e-010.067
59307SIGIRRLZE20THumanEsophagusESCC4.08e-061.66e-010.0662
59307SIGIRRLZE22D1HumanEsophagusHGIN3.56e-092.51e-010.0595
59307SIGIRRLZE24THumanEsophagusESCC9.86e-331.01e+000.0596
59307SIGIRRLZE6THumanEsophagusESCC2.17e-164.64e-010.0845
59307SIGIRRP1T-EHumanEsophagusESCC7.13e-167.80e-010.0875
59307SIGIRRP2T-EHumanEsophagusESCC1.19e-287.15e-010.1177
59307SIGIRRP4T-EHumanEsophagusESCC5.86e-244.88e-010.1323
59307SIGIRRP5T-EHumanEsophagusESCC1.63e-091.10e-010.1327
59307SIGIRRP8T-EHumanEsophagusESCC3.06e-223.77e-010.0889
59307SIGIRRP9T-EHumanEsophagusESCC2.22e-216.20e-010.1131
59307SIGIRRP11T-EHumanEsophagusESCC3.96e-321.37e+000.1426
59307SIGIRRP12T-EHumanEsophagusESCC1.74e-263.46e-010.1122
59307SIGIRRP15T-EHumanEsophagusESCC1.14e-438.53e-010.1149
59307SIGIRRP16T-EHumanEsophagusESCC2.78e-05-2.15e-020.1153
59307SIGIRRP17T-EHumanEsophagusESCC1.60e-116.69e-010.1278
59307SIGIRRP19T-EHumanEsophagusESCC4.74e-088.05e-010.1662
59307SIGIRRP20T-EHumanEsophagusESCC2.27e-317.71e-010.1124
Page: 1 2 3 4 5 6 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:00028325EsophagusHGINnegative regulation of response to biotic stimulus25/2587108/187235.87e-034.77e-0225
GO:00510908EsophagusESCCregulation of DNA-binding transcription factor activity252/8552440/187235.22e-076.97e-06252
GO:00028318EsophagusESCCregulation of response to biotic stimulus191/8552327/187232.12e-062.45e-05191
GO:00607595EsophagusESCCregulation of response to cytokine stimulus103/8552162/187233.14e-063.53e-05103
GO:000283212EsophagusESCCnegative regulation of response to biotic stimulus72/8552108/187238.36e-068.11e-0572
GO:00019595EsophagusESCCregulation of cytokine-mediated signaling pathway95/8552150/187239.48e-069.04e-0595
GO:003249619EsophagusESCCresponse to lipopolysaccharide191/8552343/187231.11e-047.73e-04191
GO:000223719EsophagusESCCresponse to molecule of bacterial origin194/8552363/187231.64e-037.61e-03194
GO:00434332EsophagusESCCnegative regulation of DNA-binding transcription factor activity103/8552185/187233.86e-031.57e-02103
GO:007122215EsophagusESCCcellular response to lipopolysaccharide113/8552209/187238.79e-033.10e-02113
GO:00316633EsophagusESCClipopolysaccharide-mediated signaling pathway37/855260/187239.17e-033.19e-0237
GO:007121617EsophagusESCCcellular response to biotic stimulus131/8552246/187239.85e-033.39e-02131
GO:00069531LiverCirrhoticacute-phase response23/463449/187236.06e-044.67e-0323
GO:00324966LiverCirrhoticresponse to lipopolysaccharide111/4634343/187238.15e-045.95e-03111
GO:0002832LiverCirrhoticnegative regulation of response to biotic stimulus41/4634108/187231.56e-031.01e-0241
GO:00022376LiverCirrhoticresponse to molecule of bacterial origin113/4634363/187233.23e-031.81e-02113
GO:00025261LiverCirrhoticacute inflammatory response40/4634112/187236.16e-033.06e-0240
GO:00028311LiverCirrhoticregulation of response to biotic stimulus101/4634327/187236.58e-033.25e-02101
GO:00028321LiverHCCnegative regulation of response to biotic stimulus66/7958108/187237.24e-056.50e-0466
GO:00028312LiverHCCregulation of response to biotic stimulus173/7958327/187238.55e-057.48e-04173
Page: 1 2 3 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
SIGIRRSNVMissense_Mutationc.890N>Tp.Ser297Phep.S297FQ6IA17protein_codingdeleterious(0)probably_damaging(0.998)TCGA-DR-A0ZM-01Cervixcervical & endocervical cancerFemale<65III/IVUnspecificCisplatinSD
SIGIRRSNVMissense_Mutationc.300N>Gp.Ile100Metp.I100MQ6IA17protein_codingdeleterious(0.04)benign(0.233)TCGA-DR-A0ZM-01Cervixcervical & endocervical cancerFemale<65III/IVUnspecificCisplatinSD
SIGIRRSNVMissense_Mutationc.979G>Ap.Asp327Asnp.D327NQ6IA17protein_codingdeleterious(0)probably_damaging(0.999)TCGA-A6-6781-01Colorectumcolon adenocarcinomaMale<65III/IVChemotherapyoxaliplatinSD
SIGIRRSNVMissense_Mutationc.626A>Gp.Glu209Glyp.E209GQ6IA17protein_codingtolerated(0.06)benign(0.039)TCGA-D5-6927-01Colorectumcolon adenocarcinomaMale<65I/IIUnknownUnknownSD
SIGIRRSNVMissense_Mutationrs147250692c.917C>Tp.Ala306Valp.A306VQ6IA17protein_codingdeleterious(0.05)possibly_damaging(0.81)TCGA-F5-6814-01Colorectumrectum adenocarcinomaMale<65I/IIUnknownUnknownSD
SIGIRRSNVMissense_Mutationc.193N>Ap.His65Asnp.H65NQ6IA17protein_codingtolerated(0.58)benign(0.001)TCGA-B5-A11J-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
SIGIRRSNVMissense_Mutationnovelc.1159N>Ap.Val387Ilep.V387IQ6IA17protein_codingtolerated(0.51)benign(0.013)TCGA-B5-A3FC-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
SIGIRRSNVMissense_Mutationnovelc.358N>Ap.Ala120Thrp.A120TQ6IA17protein_codingtolerated(0.07)benign(0.022)TCGA-B5-A3FC-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
SIGIRRSNVMissense_Mutationnovelc.1034N>Cp.Asp345Alap.D345AQ6IA17protein_codingtolerated(0.05)benign(0.115)TCGA-BS-A0UV-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVUnknownUnknownSD
SIGIRRSNVMissense_Mutationc.157N>Tp.Gly53Trpp.G53WQ6IA17protein_codingdeleterious(0)probably_damaging(0.994)TCGA-D1-A160-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
Page: 1 2 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
59307SIGIRRNAagonist178102770
Page: 1